Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus Roll-over Study
NCT02017860Phase 2
Key facts
- Status
- Completed
- Start
- Jan 2014
- Primary completion
- Apr 2019
- Countries
- 1
- Sponsor
- Novartis
- Modality
- Small Molecules
- Drugs
- everolimus
- Conditions
- Neoplasm
01
Overview
Phase 2, open-label, single-arm trial of everolimus in Neoplasm, sponsored by Novartis. Primary endpoint: Number of Participants With Adverse Events as a Measure of Safety and Tolerability up to 5 years. Started Jan 2014; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Everolimus
Patients receiving everolimus (with or without Sandostatin LAR Depot) from parent study continue treatment.
03
Who it enrols
Patients currently enrolled in a Novartis-sponsored, CD&MA study receiving everolimus or everolimus plus Sandostatin LAR Depot who have fulfilled all requirements in the parent study and are benefiting from treatment.
04
Endpoints
Primary
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Beyond the preview
Go deeper on NCT02017860.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02017860.